Bullish & Foolish
Full CABA fundamentals All 466 on the Survival Watch

CABACABALETTA BIO, INC.

Is Cabaletta Bio struggling financially?

Yes, by its own account. Cabaletta Bio told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$530.7M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 17months

    If the burn speeds up

    Empty by Nov 2027

  • 24months

    If it eases off

    Empty by Jun 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$225.1M

÷

Cash burned over the last 12 months

$132.3M

What Cabaletta Bio told the SEC

…retain our key employees, consultants and advisors and to attract, retain and motivate other qualified personnel. We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into mid-2027, we may be forced to delay, reduce or discontinue our product…

CABALETTA BIO, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 133.8% share-count increase The company issued stock. Each share now owns 57.2% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 28% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt